PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11853686-0	2002	Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.	avasimibe	123-132	carboxylesterase 1	Homo sapiens	152-196	
12360153-4	2002	METHODS: This report describes the design and methodologic features of a double-blind, randomized, placebo-controlled trial to assess the effect of the ACAT inhibitor avasimibe at 50-, 250-, and 750-mg daily dosages on the progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS).	avasimibe	167-176	carboxylesterase 1	Homo sapiens	152-156	
11853686-0	2002	Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.	avasimibe	123-132	carboxylesterase 1	Homo sapiens	198-202	
11853686-0	2002	Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.	avasimibe	134-141	carboxylesterase 1	Homo sapiens	152-196	
11853686-0	2002	Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.	avasimibe	134-141	carboxylesterase 1	Homo sapiens	198-202	
11853686-1	2002	We have studied the cellular and molecular mechanisms involved in the suppression of apoB secretion from HepG2 cells following incubation with avasimibe (CI-1011), a novel inhibitor of acyl-coenzyme A: cholesterol acyltransferase (ACAT).	avasimibe	143-152	carboxylesterase 1	Homo sapiens	185-229	
11853686-1	2002	We have studied the cellular and molecular mechanisms involved in the suppression of apoB secretion from HepG2 cells following incubation with avasimibe (CI-1011), a novel inhibitor of acyl-coenzyme A: cholesterol acyltransferase (ACAT).	avasimibe	143-152	carboxylesterase 1	Homo sapiens	231-235	
11853686-1	2002	We have studied the cellular and molecular mechanisms involved in the suppression of apoB secretion from HepG2 cells following incubation with avasimibe (CI-1011), a novel inhibitor of acyl-coenzyme A: cholesterol acyltransferase (ACAT).	avasimibe	154-161	carboxylesterase 1	Homo sapiens	185-229	
20613640-2	2010	Here, we assessed the efficacy of CI-1011, an inhibitor of acyl-coenzyme A:cholesterol acyltransferase, which is suitable for clinical use, in reducing amyloid pathology in both young (6.5 months old) and aged (16 months old) human APP transgenic mice.	avasimibe	34-41	carboxylesterase 1	Homo sapiens	59-102	
15533865-0	2004	Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.	avasimibe	69-78	carboxylesterase 1	Homo sapiens	15-58	
15533865-2	2004	The ACAT inhibitor avasimibe was shown to reduce experimental atherosclerosis.	avasimibe	19-28	carboxylesterase 1	Homo sapiens	4-8	
14644397-1	2003	This study assessed the efficacy and safety of avasimibe (CI-1011), an inhibitor of acyl coenzyme A-cholesterol acyltransferase (ACAT) in subjects with homozygous familial hypercholesterolemia (HoFH).	avasimibe	58-65	carboxylesterase 1	Homo sapiens	129-133	
15678619-1	2004	This study tested the hypothesis that avasimibe, an inhibitor of acyl coenzyme A-cholesterol acyltransferase (ACAT), would improve treadmill exercise performance in patients with claudication secondary to peripheral arterial disease (PAD).	avasimibe	38-47	carboxylesterase 1	Homo sapiens	65-108	
15678619-1	2004	This study tested the hypothesis that avasimibe, an inhibitor of acyl coenzyme A-cholesterol acyltransferase (ACAT), would improve treadmill exercise performance in patients with claudication secondary to peripheral arterial disease (PAD).	avasimibe	38-47	carboxylesterase 1	Homo sapiens	110-114	
14644397-0	2003	Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.	avasimibe	0-9	carboxylesterase 1	Homo sapiens	14-18	
14644397-1	2003	This study assessed the efficacy and safety of avasimibe (CI-1011), an inhibitor of acyl coenzyme A-cholesterol acyltransferase (ACAT) in subjects with homozygous familial hypercholesterolemia (HoFH).	avasimibe	47-56	carboxylesterase 1	Homo sapiens	84-127	
14644397-1	2003	This study assessed the efficacy and safety of avasimibe (CI-1011), an inhibitor of acyl coenzyme A-cholesterol acyltransferase (ACAT) in subjects with homozygous familial hypercholesterolemia (HoFH).	avasimibe	47-56	carboxylesterase 1	Homo sapiens	129-133	
14644397-1	2003	This study assessed the efficacy and safety of avasimibe (CI-1011), an inhibitor of acyl coenzyme A-cholesterol acyltransferase (ACAT) in subjects with homozygous familial hypercholesterolemia (HoFH).	avasimibe	58-65	carboxylesterase 1	Homo sapiens	84-127